UnitedHealth Group is recommended as a BUY for long-term investors due to its expected earnings rebound and strong market position. The company projects a 12% annual growth in earnings per share (EPS) and an average annual total return of about 18% through 2030. It maintains a solid balance sheet and a resilient business model, positioning it to gain market share as weaker competitors exit. Additionally, UnitedHealth offers a secure 2.9% dividend yield with a 16-year record of dividend growth and an expected dividend compound annual growth rate (CAGR) of 7.5%, making it attractive for income growth investors.
Piper Sandler raised its price target for UnitedHealth Group to $475, suggesting a 13.3% upside from its current price of $419.23. The company, the largest U.S. health insurer, has consistently beaten earnings estimates, with its latest EPS of $7.23 ...
The SCHD ETF has returned just under 2% in the past month, outperforming the S&P 500 ETF (SPY) by nearly 1%. Year-to-date, about 30 SCHD holdings have more than doubled the returns of SPY, which has returned 9.8%. Additionally, 31 SCHD holdings are t...
Elevance Health and UnitedHealth Group, two of the largest U.S. health insurers, are set to report their second-quarter earnings this week. Investors and analysts are watching closely to see if these companies have maintained control over rising medi...
